Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. by Ueno, Takayuki et al.
Title
Evaluating the 21-gene assay Recurrence Score® as a predictor
of clinical response to 24 weeks of neoadjuvant exemestane in
estrogen receptor-positive breast cancer.
Author(s)
Ueno, Takayuki; Masuda, Norikazu; Yamanaka, Takeharu;
Saji, Shigehira; Kuroi, Katsumasa; Sato, Nobuaki; Takei,
Hiroyuki; Yamamoto, Yutaka; Ohno, Shinji; Yamashita,
Hiroko; Hisamatsu, Kazufumi; Aogi, Kenjiro; Iwata, Hiroji;
Sasano, Hironobu; Toi, Masakazu
CitationInternational journal of clinical oncology (2013), 19(4): 607-613
Issue Date2013-10-08
URL http://hdl.handle.net/2433/198719






Evaluating the 21-Gene Assay Recurrence Score® as a Predictor of Clinical Response to 24 
Weeks of Neoadjuvant Exemestane in Estrogen Receptor-Positive Breast Cancer 
Takayuki Ueno, MD, PhD1*; Norikazu Masuda, MD, PhD2*; Takeharu Yamanaka, PhD3; 
Shigehira Saji, MD, PhD 4, 5; Katsumasa Kuroi, MD, PhD 5; Nobuaki Sato, MD6; Hiroyuki Takei, 
MD, PhD7; Yutaka Yamamoto, MD, PhD8; Shinji Ohno, MD, PhD3; Hiroko Yamashita, MD, 
PhD9; Kazufumi Hisamatsu, MD10; Kenjiro Aogi, MD, PhD11; Hiroji Iwata, MD, PhD12; 
Hironobu Sasano, MD, PhD13; Masakazu Toi, MD, PhD1 
Affiliations: 1Breast Surgery, Kyoto University Hospital, Kyoto, Japan; 2National Hospital 
Organization Osaka National Hospital, Osaka, Japan; 3National Kyushu Cancer Center, Fukuoka, 
Japan; 4 Department of  Target Therapy Oncology, Kyoto University Graduate School of 
Medicine, Kyoto, Japan; 5Tokyo Metropolitan Cancer and Infectious Diseases Center 
Komagome Hospital, Tokyo, Japan; 6Niigata Cancer Center Hospital, Niigata, Japan; 7Division 
of Breast Surgery, Saitama Cancer Center, Saitama, Japan; 8Department of Breast and Endocrine 
Surgery, Kumamoto University, Kumamoto, Japan; 9Nagoya City University Graduate School of 
Medical Sciences, Nagoya, Japan; 10Hiroshima City Asa Hospital, Hiroshima, Japan; 11National 
Hospital Organization Shikoku Cancer Center, Ehime, Japan; 12Aichi Cancer Center Hospital, 
Nagoya, Japan; 13Tohoku University School of Medicine, Sendai, Japan 
Correspondence to: Masakazu Toi 
Department of Breast Surgery, Graduate School of Medicine, Kyoto University 












The aim of this study was to investigate the association of the Recurrence Score (RS) result with 
the clinical response to neoadjuvant endocrine therapy in postmenopausal women with breast 
cancer. 
Methods 
Core biopsy samples at baseline and post-treatment surgical samples were obtained from 80 and 
77 of 116 patients, respectively, enrolled onto the multicenter prospective study of neoadjuvant 
exemestane therapy, JFMC34-0601. The 21 gene assay was performed after appropriate manual 
microdissection. Estrogen receptor (ER), progesterone receptor (PgR), HER2 and Ki-67 by 
immunohistochemistry were centrally evaluated.  Clinical response was assessed based on the 
RECIST criteria. 
Results 
Sixty-four core biopsy samples and 52 resection samples met the Recurrence Score quality 
requirements. The clinical response rate in the low RS group (19/32, 59.4%) was significantly 
higher than that in the high RS group (3/15, 20.0%) (P = 0.015) and similar to that in the 
intermediate RS group (10/17, 58.8%).  Breast conserving surgery (BCS) rates were 90.6% 
(29/32) in the low RS group, 76.5% (13/17) in the intermediate RS group and 46.7% (7/15) in 
the high RS group. The odds ratio for BCS adjusted for continuous baseline Ki-67 was 0.114 
(95% CI, 0.014 to 0.721; P = 0.028) between the high and low RS groups. Recurrence Score 
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values in pre-treatment samples were highly correlated with those in post-treatment samples 
(Spearman correlation coefficient 0.745, 95% CI 0.592-0.846).  
Conclusion 
We demonstrated the predictive value of Recurrence Score results for clinical response to 
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Recurrence Score (RS) was compared with the clinical response to neoadjuvant exemestane 
therapy in postmenopausal patients with ER-positive breast cancer. Baseline RS showed 





Neoadjuvant therapy of breast cancer has potential advantages in improving outcomes in women 
with operable and inoperable early stage disease [1, 2].  Both neoadjuvant chemotherapy and 
endocrine therapy have been shown to enable less extensive resection and improve rates of 
breast-conserving surgery (BCS) [3-6].  The ACOSOG Z1031 trial, which compared three 
aromatase inhibitors in neoadjuvant settings, showed that 51%  (81/159)  of the patients who 
were designated candidates for mastectomy experienced down staging to BCS [7].  Neoadjuvant 
endocrine therapy is now an acceptable option for postmenopausal patients with endocrine 
responsive disease [8]. 
Despite the use of standard biomarkers, considerable heterogeneity of response to therapy still 
represents a challenge for clinical decision making when considering neoadjuvant therapy. The 
ability to better identify which patients will respond to therapy would represent a major clinical 
advance.  Although Ki-67 labeling index (LI) shows some consistency in predicting response to 
chemotherapy, its ability to predict response to neoadjuvant endocrine therapy is controversial 
[9, 10]. 
We previously reported results from a neoadjuvant exemestane study in postmenopausal women 
[11].  In the study, the objective response rate was 51% (59/116) and 40 (77%) of 59 patients 
who would have required mastectomy were converted to BCS.  Neither baseline Ki-67 LI nor 
changes in Ki-67 LI were associated with clinical response in the study.  
The Oncotype DX® assay has been shown to assess recurrence risk in women with hormone 
receptor positive (HR+), lymph node negative or positive, early stage breast cancer who are 
treated with adjuvant endocrine therapy [12-15].  It has also been shown to predict the likelihood 
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of benefit from adjuvant chemotherapy [12, 16].  Accordingly, the assay is included in clinical 
guidelines for use in patients with HR+ lymph node negative disease; however, its applicability 
to HR+ postmenopausal women with lymph node positive disease is considered controversial, 
pending results of the RxPONDER trial [8, 17-19].  Additionally, studies in the neoadjuvant 
setting have shown that the test can be used to predict the response to chemotherapy [20, 21].   
More recently, a study suggested that the Recurrence Score may predict responses to 
neoadjuvant endocrine therapy with either tamoxifen or anastrozole [22].   The Oncotype DX 
assay may improve the ability to discriminate between clinically similar tumors based on the 
tumor’s underlying biology.  This study was conducted to investigate the clinical usefulness of 
the Recurrence Score result for prediction of the response to neoadjuvant endocrine therapy.    
Methods: 
Study Design 
This was a prospectively designed study using archived tumor tissues from the previously 
conducted JFMC34-0601 study.  The primary objective was to assess the association between the 
Recurrence Score result at baseline and clinical response, by comparing the response rates 
between the low (<18) and high (≥31) Recurrence Score groups.  Secondary objectives included 
assessment of the associations of continuous baseline Recurrence Score, quantitative estrogen 
receptor (ER) by RT-PCR and Ki-67 with clinical response and with BCS, as well as 
associations of changes from baseline to post-treatment values of these markers with clinical 
response.  The study protocol was approved by the Ethics Committee in each institution. 
Informed consent was obtained from all patients. The study was performed in accordance with 
the Helsinki Declaration. 
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Patient Cohort and Tumor Samples 
Eligibility criteria for the parent JFMC34-0601 study included: age 55-75 years, ER+ and stage 
II or IIIa invasive breast cancer (T2-3, N0-2, M0).  Patients were confirmed positive for ER or 
progesterone receptor (PgR) by IHC (≥10% nuclear staining).  Study treatment was 25 mg/day 
exemestane for 16 weeks with an 8-week extension according to the assessment of clinical 
response. Patients with progressive disease (PD) were withdrawn from the study.  At week 24, 
patients underwent surgery, except those with PD, who had the option of selecting another 
treatment approach.   
Clinical Outcomes Measures 
Clinical response was assessed by comparing the longest diameter of the target lesions with the 
baseline measurement, based on Response Evaluation Criteria in Solid Tumors (RECIST) 
criteria version 1.0 by caliper measurement of palpable lesions and ultrasound as previously 
described [11]. Briefly, complete response (CR) was defined by disappearance of all target 
lesions; partial response (PR) by at least a 30% decrease in the sum of diameters of target 
lesions; PD by at least a 20% increase in the sum of diameters of target lesions; stable disease 
(SD) by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.  
Biomarker Assessments 
The Oncotype DX® 21-gene assay was performed on core biopsy and resection samples by 
Genomic Health [14].   
Ki-67, ER and PgR by IHC were performed centrally and assessed by three independent 
pathologists as described previously [11]. In brief, IHC staining was performed using a Histofine 
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Kit (Nichirei, Tokyo, Japan). The Ki-67 was stained using the following antibody dilution: 1:100 
(Dako, Glostrup, Denmark).  Ki-67 LI was obtained by counting 500 to 1000 tumor cells at the 
sites of hot spots.  Ki-67 groups were defined post-hoc as <10, 10-30, and >30%.  ER and PgR 
immuno-reactivity were scored according to Allred’s procedure. 
Expression of HER2 was determined by the HercepTest (Dako). Positive HER2 status was 
defined as either 3+ or 2+ with confirmed c-erbB2 gene amplification by the FISH test. 
Statistical Analyses 
Analyses of baseline markers included all patients with an evaluable RT-PCR result from core 
biopsies.  Analyses of changes from baseline to post-treatment markers included the subset of 
patients with results from both core biopsies and surgical resections.  Changes of continuous 
markers were defined as “post-treatment value - pre-treatment value”.  In the primary analysis, 
the rates of clinical response were compared between the high and low baseline Recurrence 
Score groups using Fisher’s exact test. Logistic regression models were fit to both clinical 
response and surgery type.  Odds ratio (OR) estimates are presented with Wald p-values and 
95% confidence intervals (CIs).  All p-values are two-sided.  In exploratory analyses, the 
Spearman rank correlation coefficient (and associated 95% CI) was calculated for baseline 
continuous Recurrence Score and either post-treatment Recurrence Score or baseline continuous 
Ki-67 by IHC. A paired t-test was applied to compare baseline and post-treatment Recurrence 
Score values. A two-sample t-test was used to compare the percent reduction in tumor size 
between the high and low Recurrence Score groups. Fisher’s exact test was used to compare the 





One hundred sixteen patients were enrolled in JFMC34-0601 between March 2006 and 
December 2007.   One hundred two patients completed 24 weeks of neoadjuvant exemestane 
treatment [11].  Core biopsy and resection samples were obtained for 80 (69%) and 77 (66%) 
patients, respectively.  Of the 157 samples sent for Oncotype DX testing, 2 were deemed 
ineligible per blinded Genomic Health pathology review.  Insufficient RNA (<375ng) was 
extracted from 18 samples (15 core biopsy and 3 resection).  Standard quality metrics were not 
met for 8 samples (all resections), leaving 64 core biopsy samples, of which 52 had matching 
resection samples with evaluable RT-PCR results.  
Baseline characteristics and clinical outcomes for the 64 patients are shown in Table 1. Forty-
nine (76.6%) patients had BCS while 32 patients (50%) had been candidates for BCS before the 
treatment.  Four patients refused surgery after exemestane therapy and are treated as not BCS.  
In the primary analysis, the clinical response rate in the low Recurrence Score group 
(19/32=59.4%) was significantly higher than that in the high Recurrence Score group 
(3/15=20.0%) (p=0.015) (Table 2). The clinical response rate in the intermediate risk group 
(10/17=58.8%) was similar to that in the low risk group.  When analyzed by logistic regression, 
the OR for clinical response between the intermediate and low Recurrence Score groups was 
0.977 (95% CI 0.296-3.233, p=0.970) and between the high and low Recurrence Score groups 
was 0.171 (95% CI 0.040-0.728, p=0.017). In an exploratory analysis, percent reduction in tumor 
size determined by ultrasound was compared between low and high Recurrence Score groups. 
Patients in the low Recurrence Score group showed 31.8% reduction in size on average while 
those in the high Recurrence Score group showed 12.5% reduction, indicating significant 
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difference between the groups (p=0.045). The average reduction (27.6%) in patients in the 
intermediate risk group was similar to that in the low risk group. 
When treated as a continuous variable, the baseline Recurrence Score was significantly 
associated with clinical response in a logistic regression analysis (p=0.042, Table 3). There was a 
trend between continuous baseline ER by RT-PCR and clinical response (p=0.076). Continuous 
baseline Ki-67 by IHC was not associated with clinical response (p=0.273). 
The associations between changes from baseline to post-treatment values of continuous markers 
and clinical response were examined in logistic regression analyses.  Changes in Recurrence 
Score, ER by RT-PCR, and Ki-67 by IHC were not associated with clinical response (p=0.240, 
p=0.343, and p=0.629, respectively). 
Analysis of Recurrence Score categories and BCS is shown in Table 2.  The OR for BCS 
between the intermediate and low Recurrence Score groups was 0.336 (95% CI 0.066-1.722, 
p=0.19) and between the high and low Recurrence Score groups was 0.091 (95% CI 0.019-0.432, 
p=0.003). The logistic regression analyses of continuous baseline Recurrence Score, ER by RT-
PCR and Ki-67 by IHC with BCS are shown in Table 3.  Continuous baseline Recurrence Score 
was significantly associated with BCS in both unadjusted (p=0.001) and covariate-adjusted (for 
tumor size and PgR) (p=0.004) analyses.  Continuous baseline ER by RT-PCR was also 
significantly associated with BCS in both unadjusted (p=0.001) and covariate-adjusted (p=0.023) 
analyses.  Continuous baseline Ki-67 by IHC was significantly associated with BCS in 
unadjusted analysis (p=0.024) but lost its significance when adjusted for tumor size and PgR 
(p=0.060). When both continuous Recurrence Score values and continuous Ki-67 were included 
in the logistic regression model for BCS, the Recurrence Score retained its statistical significance 
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(p=0.012) whereas Ki-67 did not (p=0.868). The conversion rate from mastectomy planned at 
baseline to BCS performed after the treatment was 88% (15/17) in the low Recurrence Score 
group, 70% (7/10) in the intermediate Recurrence Score group and 20% (1/5) in the high 
Recurrence Score group. The rate was significantly different among groups (p=0.010). 
The associations between Recurrence Score and Ki-67, and their respective and joint 
associations with BCS were examined in exploratory analyses. Figure 1(a) is a scatter plot of 
baseline Ki-67 by IHC vs. baseline Recurrence Score results. The Spearman correlation 
coefficient was 0.672 (95% CI 0.506-0.785). All patients with PD had high Recurrence Score 
values (range: 32 - 73) while three of five PD patients showed intermediate Ki-67 LI {Figure 
1(a)}.  
No statistically significant difference was observed between baseline and post-treatment 
Recurrence Score values (p=0.484). A scatter plot is shown in Figure 1(b).  The Spearman 
correlation analysis showed a high correlation (correlation coefficient 0.745, 95% CI 0.592-
0.846).   
Discussion: 
In this study, we demonstrated the predictive value of Recurrence Score results for response to 
neoadjuvant endocrine therapy. Patients with low scores showed a better response to neoadjuvant 
endocrine therapy than those with high scores. Since patients with high Recurrence Score results 
have been shown to benefit from chemotherapy, the 21-gene assay may provide additional 
information in selecting neoadjuvant treatment with endocrine therapy for low Recurrence Score 
and chemotherapy for high Recurrence Score cancers.  
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ER Allred scores have been reported to correlate with response rates to neoadjuvant letrozole or 
tamoxifen.  The P024 trial of neoadjuvant letrozole or tamoxifen showed that tumors with low 
ER Allred scores still responded to letrozole [23]. Conversely, some tumors with higher ER 
levels did not respond to endocrine therapy [23, 24]. Gene expression-based profiles categorize 
HR+, HER2- breast cancers into two subtypes: luminal-A and luminal-B [25]. However, the 
classification, as determined by PAM50, is reported not to relate to clinical response or the 
likelihood of BCS after neoadjuvant AI treatment [7].   
In our study, Recurrence Score was the only predictive factor for clinical responses to 
neoadjuvant endocrine therapy and the most potent predictive factor for BCS in the covariate-
adjusted analysis.  These results are consistent with other studies that suggest that low 
Recurrence Score can predict benefit from endocrine therapy [22, 24]. The study by Kim et al. 
compared the outcomes of the tamoxifen and placebo arms of the NSABP B14 trial and 
demonstrated that higher levels of quantitative ER expression by RT-PCR correlated with greater 
benefit from adjuvant tamoxifen as measured by distant recurrence [24]. 
Our results indicate that Recurrence Score values before and after endocrine therapy were highly 
correlated. Since a number of studies have suggested that post-treatment biomarkers such as Ki-
67 LI and ER have better prognostic values than pre-treatment biomarkers, post-treatment 
biomarkers are receiving increasing interest for patient stratification in clinical trials [26-28]. 
Dowsett et al. reported the results of an unplanned, exploratory investigation of the relationship 
between post-treatment Ki-67 (2 weeks) and recurrence free survival (RFS) using archived 
tumors from the IMPACT study [26].  Their results indicated that post-treatment Ki-67, larger 
baseline tumor size, and post-treatment ER level were significantly correlated with DFS.  Ellis et 
al. analyzed the ability of post-treatment Ki-67 and other factors (tumor size, grade, nodal status, 
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and post-treatment ER expression) to predict RFS and breast cancer specific survival using 
archived tumors from the P024 study [27]. An interesting study (ACOSOG Z1031, Cohort B) 
has been conducted to determine whether patients with a high Ki-67 value after two weeks of 
neoadjuvant AI treatment show a higher than expected pCR rate to neoadjuvant chemotherapy 
than would be typically observed for those patients with unselected ER-rich tumors and will tell 
us whether assessment of Ki-67 two weeks after neoadjuvant AI treatment is useful for the 
identification of a chemotherapy sensitive subgroup of ER+ tumors. However, even if this is the 
case, intervention of two weeks AI treatment and re-biopsy are necessary. Although further 
investigations are needed, the comparative stability of Recurrence Score would improve the 
decision making of the whole treatment before the initiation of treatment.  
This study’s primary limitation was small sample size. Availability of tumor samples from the 
parent study was limited and recovery of mRNA was not uniformly adequate. Further 
investigation in larger prospective studies would better define candidates for neoadjuvant 
endocrine therapy. Another limitation was no assessment of lymph node response. Although 
nodal response is clinically relevant, considering one of the major purposes of neoadjuvant 
endocrine therapy is improvement in surgical outcome, the clinical response in the primary site 
and the BCS rate are also of clinical importance for the assessment of the effect of neoadjuvant 
endocrine therapy.  
In conclusion, this study showed a predictive value of Recurrence Score results for clinical 
response to neoadjuvant exemestane therapy. The 21-gene assay shows promise for providing 
useful information to guide neoadjuvant treatment selection for systemic therapy, with 
neoadjuvant endocrine treatment for patients with low Recurrence Score disease and neoadjuvant 
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(a) Scatterplot of Baseline RS and Baseline Ki-67, with Spearman Correlation Coefficient 
The Spearman correlation coefficient between baseline RS and baseline Ki67 was 0.672 (95% CI 
0.506-0.785).  None of five patients with tumor progression was in the low or intermediate RS 
groups.  
(b) Scatterplot of Baseline RS and Post-treatment RS, with Spearman Correlation Coefficient 
Baseline RS was highly correlated with RS in post-treatment samples (Spearman correlation 






Table 1: Baseline Patient Characteristics and Clinical Outcomes (n=64) 
Feature n (%) Feature n (%) 
Age (years) HER2 by IHC/FISH  
55-64 34 (53.1%) Negative 50 (78.1%) 
65-74 25 (39.1%) Positive 2 (3.1%) 
75-77 5 (7.8%) Unknown 12 (18.8%) 
    
Tumor Stage at baseline RS Risk Group  
T2 62 (96.9%) Low (< 18) 32 (50.0%) 
T3 2 (3.1%) Intermediate (18 - 30) 17 (26.6%) 
  High (≥ 31) 15 (23.4%) 
Stage   
IIA 47 (73.4%) Ki-67 by IHC (%)  
IIB 15 (23.4%) <10 28 (43.8%) 
IIIA 2 (3.1%) 10-30 23 (35.9%) 
  >30 13 (20.3%) 
ER by IHC (Allred Score)   
4 1 (1.6%) Clinical Response  
5 3 (4.7%) CR 0 
6 5 (7.8%) PR 32 (50.0%) 
7 14 (21.9%) SD 24 (37.5%) 
8 41 (64.1%) PD 5 (7.8%) 
  NE 3 (4.7%) 
ER Status by RT-PCR    
ER- (≤6.5CT) 1 (1.5%) Surgery Type  
ER+ (>6.5CT) 63 (98.4%) Breast-Conserving 49 (76.6%) 
  Mastectomy 11 (17.2%) 
PgR by IHC (Allred Score) No surgery 4 (6.3%) 
0 4 (6.25%) 
4 7 (10.94%) 
5 4 (6.25%) 





PgR Status by RT-PCR  
PgR- (≤ 5.5 CT) 14 (21.9%) 





Table 2: Clinical Response and BCS according to Categorical Baseline RS 
RS Risk Group Clinical Response Proportion(Response Rate)* Odds Ratio(95% CI) p-value 
Low (RS <18) 19/32(59.4%) 1 n/a 
Int. (RS 18 - 30) 10/17(58.8%) 0.977(0.296, 3.233) 0.970 
High (RS ≥31) 3/15(20.0%) 0.171(0.040, 0.728) 0.017 
RS Risk Group Breast-Conserving Surgery Proportion(BCS Rate) Odds Ratio(95% CI) p-value 
Low (RS <18) 29/32(90.6%) 1 n/a 
Int. (RS 18 - 30) 13/17(76.5%) 0.336(0.066, 1.722) 0.19 
High (RS ≥31) 7/15(46.7%) 0.091(0.019, 0.432) 0.003 
*Primary analysis: p=0.015 by Fisher’s exact test for comparison of clinical response rates between the 






Table 3: Continuous Baseline RS, ER by RT-PCR and Ki-67 by IHC and Clinical Response and Breast-






ER by RT-PCR  
(log2 increase) 
Ki-67 by IHC 
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* Adjusted for tumor size and PgR Allred score, which were significantly associated with breast-
conserving surgery in univariable analyses. 
 

